簇集蛋白在心血管疾病中的研究进展

doi:10.3969/j.issn.1004-583X.2022.09.016

摘要/Abstract

摘要：

簇集蛋白(clusterin,CLU),又称为载脂蛋白J,是一种新型脂肪因子。可在多种组织中表达,如心脏、胰腺、肾脏、脑、睾丸、前列腺等,并参与机体的脂质转运、细胞凋亡、氧化应激、炎症反应等过程。与心血管疾病、肥胖相关代谢性疾病、肿瘤、神经退行性病变等相关,并与疾病严重程度有一定的关系,提示CLU可能在疾病进展过程中发挥一定的保护作用,因此CLU有可能成为上述疾病潜在的预测因子。本文就CLU在心血管疾病中的研究进展进行综述,旨在为临床提供依据。

关键词: 心血管疾病, 冠心病, 心力衰竭, 高血压, 心肌疾病, 聚集素

中图分类号:

王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2022.09.016

https://lchc.magtechjournal.com/CN/Y2022/V37/I9/842

参考文献 45

[1]	Lau WB, Ohashi K, Wang Y, et al. Role of adipokines in cardiovascular disease[J]. Circ J, 2017, 81(7):920-928. doi: 10.1253/circj.CJ-17-0458 pmid: 28603178
[2]	Recinella L, Orlando G, Ferrante C, et al. Adipokines:New potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases[J]. Front Physiol, 2020, 11: 578966. doi: 10.3389/fphys.2020.578966 URL
[3]	Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone[J]. Trends Biochem Sci, 2000, 25(3):95-98. pmid: 10694874
[4]	Wittwer J, Bradley D. Clusterin and its role in insulin resistance and the cardiometabolic syndrome[J]. Front Immunol, 2021, 12:612496. doi: 10.3389/fimmu.2021.612496 URL
[5]	Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid[J]. J Biol Chem, 1983, 258(12):7714-7720. pmid: 6863260
[6]	卜浩. sCLU在胰腺癌组织中的表达与其临床意义研究[D]. 湖南师范大学, 2020.
[7]	Park S, Mathis KW, Lee IK. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases[J]. Rev Endocr Metab Disord, 2014, 15(1):45-53. doi: 10.1007/s11154-013-9275-3 URL
[8]	Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases[J]. Free Radic Res, 2006, 40(12):1324-1334. doi: 10.1080/10715760600902310 URL
[9]	Boel N, Edkins A. Regulation of the extracellular matrix by heat shock proteins and molecular chaperones[J]. Heat Shock Prot Imm Syst, 2018:97-121.
[10]	Cunin P, Beauvillain C, Miot C, et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses[J]. Cell Death Dis, 2016, 7(5): e2215.
[11]	Hong SW, Lee J, Kim MJ, et al. Clusterin protects lipotoxicity-induced apoptosis via upregulation of autophagy in insulin-secreting cells[J]. Endocrinol Metab (Seoul), 2020, 35(4):943-953. doi: 10.3803/EnM.2020.768 URL
[12]	Lee J, Hong SW, Kwon H, et al. Resveratrol, an activator of SIRT1, improves ER stress by increasing clusterin expression in HepG2 cells[J]. Cell Stress Chaperones, 2019, 24(4):825-833. doi: 10.1007/s12192-019-01012-z URL
[13]	Xiao Y, Zeng M, Yin L, et al. Clusterin increases mitochondrial respiratory chain complex I activity and protects against hexavalent chromium-induced cytotoxicity in L-02 hepatocytes[J]. Toxicol Res, 2018, 8(1):15-24. doi: 10.1039/C8TX00231B URL
[14]	Ma Y, Li S, Tang S, et al. Clusterin protects against Cr(VI)-induced oxidative stress-associated hepatotoxicity by mediating the Akt-Keap1-Nrf2 signaling pathway[J]. Environ Sci Pollut Res Int, 2022, 29(34):52289-52301. doi: 10.1007/s11356-022-19118-w URL
[15]	Zhang Y, Zhang Y, Xiao Y, et al. Expression of clusterin suppresses Cr(VI)-induced premature senescence through activation of PI3K/AKT pathway[J]. Ecotoxicol Environ Saf, 2019, 183:109465. doi: 10.1016/j.ecoenv.2019.109465 URL
[16]	Li Y, Song YQ, Zhang Y, et al. Over-expression of apolipoprotein J inhibits cholesterol crystal-Induced inflammatory responses via suppressing NLRP3 inflammasome activation in THP-1 macrophages[J]. Folia Biol (Praha), 2021, 67(5-6):183-190.
[17]	Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling[J]. Circulation, 2013, 127(8):891-904. doi: 10.1161/CIRCULATIONAHA.112.108753 URL
[18]	Iłżecka J, Iłżecki M, Grabarska A, et al. Clusterin as a potential marker of brain ischemia-reperfusion injury in patients undergoing carotid endarterectomy[J]. Ups J Med Sci, 2019, 124(3):193-198. doi: 10.1080/03009734.2019.1646359 URL
[19]	Zhu H, Liu M, Zhai T, et al. High serum clusterin levels are associated with premature coronary artery disease in a Chinese population[J]. Diabetes Metab Res Rev, 2019, 35(4):e3128. doi: 10.1002/dmrr.3128 URL
[20]	Kang M, Seong Y, Mahmud J, et al. Obscurin and Clusterin Elevation in Serum of Acute Myocardial Infarction Patients[J]. Bull Korean Chem Soc, 2020, 41(3):266-273. doi: 10.1002/bkcs.11955 URL
[21]	Traxler D, Spannbauer A, Einzinger P, et al. Early elevation of systemic plasma clusterin after reperfused acute myocardial infarction in a preclinical porcine model of ischemic heart disease[J]. Int J Mol Sci, 2020, 21(13):4591. doi: 10.3390/ijms21134591 URL
[22]	Wu D, Zhang K, Hu P. The role of autophagy in acute myocardial infarction[J]. Front Pharmacol, 2019, 10:551. doi: 10.3389/fphar.2019.00551 pmid: 31214022
[23]	Turkieh A, Porouchani S, Beseme O, et al. Increased clusterin levels after myocardial infarction is due to a defect in protein degradation systems activity[J]. Cell Death Dis, 2019, 10(8): 608. doi: 10.1038/s41419-019-1857-x pmid: 31406108
[24]	Pavo N, Lukovic D, Zlabinger K, et al. Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion[J]. Oncotarget, 2017, 8(40) : 67227-67240. doi: 10.18632/oncotarget.18438 pmid: 28978029
[25]	梁鹏. 急性冠脉综合征患者血清簇集蛋白水平与冠脉狭窄程度相关性研究[D]. 河北医科大学, 2019.
[26]	Eggers KM, Lindhagen L, Baron T, et al. Erratum to: Predicting outcome in acute myocardial infarction: An analysis investigating 175 circulating biomarkers[J]. Eur Heart J Acute Cardiovasc Care, 2022, 11(1):88. doi: 10.1093/ehjacc/zuab107 URL
[27]	Bass-Stringer S, Ooi JYY, McMullen JR. Clusterin is regulated by IGF1-PI3K signaling in the heart: Implications for biomarker and drug target discovery, and cardiotoxicity[J]. Arch Toxicol, 2020, 94:1763-1768. doi: 10.1007/s00204-020-02709-2 pmid: 32172307
[28]	Koller L, Richter B, Winter MP, et al. Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure[J]. Clin Lipidol, 2017, 11(1):178-184.
[29]	Turkieh A, Fertin M, Bouvet M, et al. Expression and implication of clusterin in left ventricular remodeling after myocardial infarction[J]. Circ Heart Fail, 2018, 11(6):e004838. doi: 10.1161/CIRCHEARTFAILURE.117.004838 URL
[30]	Sirtori CR, Ruscica M, Calabresi L, et al. HDL therapy today: From atherosclerosis, to stent compatibility to heart failure[J]. Ann Med, 2019, 51(7-8):345-359. doi: 10.1080/07853890.2019.1694695 pmid: 31729238
[31]	Jenča D, Melenovský V, Stehlik J, et al. Heart failure after myocardial infarction: Incidence and predictors[J]. ESC Heart Fail, 2020, 8(1):222-237.
[32]	杨斐然. 原发性老年高血压患者血清簇集蛋白水平与血管内皮功能的相关性[D]. 河北医科大学, 2019.
[33]	Zeng S, Han M, Jiang M, et al. Serum complement proteomics reveal biomarkers for hypertension disorder of pregnancy and the potential role of clusterin[J]. Reprod Biol Endocrinol, 2021, 19(1):56. doi: 10.1186/s12958-021-00742-z URL
[34]	Kocatürk M, Baykal AT, Turkseven S, et al. Evaluation of serum and ascitic fluid proteomes in dogs with dilated cardiomyopathy[J]. Kafkas Uni Vet Fak Derg, 2016, 22: 273-279.
[35]	Roura S, Gámez-Valero A, Lupón J, et al. Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy[J]. Lab Invest, 2018, 98(10):1291-1299. doi: 10.1038/s41374-018-0044-5 pmid: 29540862
[36]	Kourelis TV, Dasari SS, Dispenzieri A, et al. A proteomic atlas of cardiac amyloid plaques[J]. JACC Cardio Oncol, 2020, 2(4):632-643.
[37]	McLaughlin L, Zhu G, Mistry M, et al. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis[J]. Clin Invest, 2000, 106(9):1105-1113. doi: 10.1172/JCI9037 URL
[38]	Pereira RM, Mekary RA, da Cruz Rodrigues KC, et al. Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes[J]. Heart Fail Rev, 2018, 23(1):123-129. doi: 10.1007/s10741-017-9654-z pmid: 28948410
[39]	Guan Q, Li S, Yip G, et al. Decrease in donor heart injury by recombinant clusterin protein in cold preservation with University of Wisconsin solution[J]. Surgery, 2012, 151(3):364-371. doi: 10.1016/j.surg.2011.09.032 URL
[40]	Du J, Liu L, Yu B, et al. Clusterin (apolipoprotein J) facilitates NF-κB and Bax degradation and prevents I/R injury in heart transplantation[J]. Int J Clin Exp Pathol, 2018, 11(3):1186-1196.
[41]	Hollander Z, Lazárová M, Lam KK, et al. Proteomic biomarkers of recovered heart function[J]. Eur J Heart Fail, 2014, 16:551-559. doi: 10.1002/ejhf.65 pmid: 24574204
[42]	Oh GS, Yoon J, Kim G, et al. Regulation of adipocyte differentiation by clusterin-mediated Krüppel-like factor 5 stabilization[J]. FASEB J, 2020, 34(12): 16276-16290. doi: 10.1096/fj.202000551RR URL
[43]	Peng M, Deng J, Zhou S, et al. The role of clusterin in cancer metastasis[J]. Cancer Manag Res, 2019, 11:2405-2414. doi: 10.2147/CMAR.S196273 pmid: 31114318
[44]	Wilson MR, Zoubeidi A. Clusterin as a therapeutic target[J]. Expert Opin Ther Targets, 2017, 21(2):201-213. doi: 10.1080/14728222.2017.1267142 URL
[45]	Foster EM, Dangla-Valls A, Lovestone S, et al. Clusterin in Alzheimer's disease: Mechanisms, genetics, and lessons from other pathologies[J]. Front Neurosci, 2019, 13:164. doi: 10.3389/fnins.2019.00164 URL

簇集蛋白在心血管疾病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵光艳, 韩拓, 梁西颖, 王倩, 张岩, 王聪霞. 中青年人群中隐匿性高血压患病危险因素与预测模型[J]. 临床荟萃, 2025, 40(3): 205-210.
[2]	胡松林, 邸雅, 刘灿章, 闫杰. 应用虚拟组织学血管内超声探讨血小板/淋巴细胞比值水平与冠心病合并2型糖尿病患者冠状动脉斑块特点的关系[J]. 临床荟萃, 2025, 40(2): 117-121.
[3]	赵晨, 王福华, 刘永华, 代燕燕, 陈文馨, 周江. 吸烟与青年冠心病相关性研究进展[J]. 临床荟萃, 2025, 40(2): 180-184.
[4]	张雪, 王俊祥. 类风湿关节炎共病的研究进展[J]. 临床荟萃, 2025, 40(1): 86-89.
[5]	张中楼, 崔坤, 孟晋启. 运动保护心血管系统的研究进展[J]. 临床荟萃, 2024, 39(9): 855-860.
[6]	马剑楠, 陶杰, 桑大森, 吴寿岭, 张旗. 尿转铁蛋白与2型糖尿病人群新发心血管疾病的关系[J]. 临床荟萃, 2024, 39(8): 700-705.
[7]	宋怡静, 李健, 宋芹, 邵莉. CRP联合TyG指数对类风湿关节炎患者发生冠心病风险的预测价值[J]. 临床荟萃, 2024, 39(6): 506-511.
[8]	王婷, 柴春艳, 李敏. 以谵妄为首发症状的老年心力衰竭病例3例并文献复习[J]. 临床荟萃, 2024, 39(5): 440-444.
[9]	庞樱容, 孙欣. sST2在心血管疾病中作用的研究进展[J]. 临床荟萃, 2024, 39(5): 460-465.
[10]	师丽琪, 雷普文, 钱宝堂. 高强度间歇训练在接受经皮冠状动脉介入治疗冠心病患者心脏康复中的研究进展[J]. 临床荟萃, 2024, 39(5): 466-469.
[11]	匡竞, 滕双芩, 申彤彤, 闫怡然, 申川, 王玮, 王亚东, 赵彩彦. 门脉性肺动脉高压研究进展[J]. 临床荟萃, 2024, 39(4): 352-356.
[12]	徐孟丹, 王礼琳. 阻塞性睡眠呼吸暂停与缺血性心肌病的关系研究进展[J]. 临床荟萃, 2024, 39(4): 357-362.
[13]	孙庆, 王海龙, 米庆, 乐暾, 牟华明. 外泌体在心力衰竭发生发展中的作用及临床价值[J]. 临床荟萃, 2024, 39(3): 259-263.
[14]	王婷, 柴春艳. 维立西呱在老年高龄射血分数降低心力衰竭患者中的应用[J]. 临床荟萃, 2024, 39(12): 1081-1084.
[15]	郝清卿, 吕仕林, 张静, 张立涛, 张飞飞. 心脏收缩力调节对慢性心力衰竭兔心肌自噬的影响及可能机制[J]. 临床荟萃, 2024, 39(11): 1026-1034.